Cargando…

Ruxolitinib for symptom control in patients with Chronic Lymphocytic leukemia: A Phase II Trial

BACKGROUND: Disease-related symptoms impair the quality of life of countless patients with chronic lymphocytic leukemia (CLL) who do not require systemic therapy. Currently available therapies are not specifically aimed at symptom control. Because stimulation of the B-cell receptor activates Janus k...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jain, Preetesh, Keating, Michael, Renner, Sarah, Cleeland, Charles, Xuelin, Huang, Gonzalez, Graciela Nogueras, Harris, David, Li, Ping, Liu, Zhiming, Veletic, Ivo, Rozovski, Uri, Jain, Nitin, Thompson, Phillip, Bose, Prithviraj, DiNardo, Courtney, Ferrajoli, Alessandra, O’Brien, Susan, Burger, Jan, Wierda, William, Verstovsek, Srdan, Kantarjian, Hagop, Estrov, Zeev
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356368/ https://www.ncbi.nlm.nih.gov/pubmed/28089238 http://dx.doi.org/10.1016/S2352-3026(16)30194-6

Ejemplares similares

STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells
por: Rozovski, Uri, et al.
Publicado: (2021)

STAT3-activated CD36 facilitates fatty acid uptake in chronic lymphocytic leukemia cells
por: Rozovski, Uri, et al.
Publicado: (2018)

STAT3 is constitutively acetylated on lysine 685 residues in chronic lymphocytic leukemia cells
por: Rozovski, Uri, et al.
Publicado: (2018)

Altered T-cell subset repertoire affects treatment outcome of patients with myelofibrosis
por: Veletic, Ivo, et al.
Publicado: (2020)

Ruxolitinib for essential thrombocythemia?
por: Bose, Prithviraj, et al.
Publicado: (2017)

Interleukin-7 receptor-α gene mutations are not detected in adult T-cell acute lymphoblastic leukemia
por: Rozovski, Uri, et al.
Publicado: (2014)

A case of lymphocytic variant hypereosinophilic syndrome with sub-diagnostic systemic mastocytosis
por: Jain, Preetesh, et al.
Publicado: (2017)

P1025: A PILOT STUDY OF THE ANTI-SLAMF7 MONOCLONAL ANTIBODY, ELOTUZUMAB, IN PATIENTS WITH MYELOFIBROSIS.
por: Bose, Prithviraj, et al.
Publicado: (2023)

GLI1 activates pro-fibrotic pathways in myelofibrosis fibrocytes
por: Manshouri, Taghi, et al.
Publicado: (2022)

Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis
por: Kvasnicka, Hans Michael, et al.
Publicado: (2018)

Efficacy and safety of pegylated interferon alpha-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV): results of a phase 2 study after a 7-year median follow-up
por: Masarova, Lucia, et al.
Publicado: (2017)

Primary myelofibrosis marrow-derived CD14(+)/CD34(-) monocytes induce myelofibrosis-like phenotype in immunodeficient mice and give rise to megakaryocytes
por: Manshouri, Taghi, et al.
Publicado: (2019)

Signal Transducer and Activator of Transcription–3 Induces MicroRNA-155 Expression in Chronic Lymphocytic Leukemia
por: Li, Ping, et al.
Publicado: (2013)

Signal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cells
por: Rozovski, Uri, et al.
Publicado: (2013)

Ruxolitinib for the treatment of myelofibrosis: its clinical potential
por: Ostojic, Alen, et al.
Publicado: (2012)

Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States
por: Abou Dalle, Iman, et al.
Publicado: (2019)

Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes
por: Verstovsek, Srdan, et al.
Publicado: (2013)

Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
por: Bryan, Jeffrey C., et al.
Publicado: (2016)

Ruxolitinib: a targeted treatment option for patients with polycythemia vera
por: Vaddi, Kris, et al.
Publicado: (2016)

Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
por: Boddu, Prajwal, et al.
Publicado: (2018)

Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
por: Verstovsek, Srdan, et al.
Publicado: (2023)

Updates in the management of polycythemia vera and essential thrombocythemia
por: Bose, Prithviraj, et al.
Publicado: (2019)

JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives
por: Bose, Prithviraj, et al.
Publicado: (2020)

MF management
por: Bose, Prithviraj, et al.
Publicado: (2019)

The BET Inhibitor GS-5829 Targets Chronic Lymphocytic Leukemia Cells and Their Supportive Microenvironment
por: Kim, Ekaterina, et al.
Publicado: (2019)

Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies
por: Thompson, Philip A., et al.
Publicado: (2018)

Membranoproliferative glomerulonephritis and acute renal failure in a patient with chronic lymphocytic leukemia: Response to obinutuzumab
por: Jain, Punit, et al.
Publicado: (2016)

Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib
por: Rajasekaran, Arun, et al.
Publicado: (2015)

A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second‐ and third‐generation tyrosine kinase inhibitors
por: Zulbaran‐Rojas, Alejandro, et al.
Publicado: (2018)

Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis COMFORT-I
por: Miller, Carole B., et al.
Publicado: (2017)

Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms
por: Bose, Prithviraj, et al.
Publicado: (2020)

Momelotinib: an emerging treatment for myelofibrosis patients with anemia
por: Chifotides, Helen T., et al.
Publicado: (2022)

Association of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and Treatments
por: Chifotides, Helen T., et al.
Publicado: (2023)

Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts
por: Talpaz, Moshe, et al.
Publicado: (2013)

A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea
por: Verstovsek, Srdan, et al.
Publicado: (2014)

Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval
por: Verstovsek, Srdan, et al.
Publicado: (2021)

Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial
por: Verstovsek, Srdan, et al.
Publicado: (2023)

Sustained‐release ruxolitinib: Findings from a phase 1 study in healthy subjects and a phase 2 study in patients with myelofibrosis
por: Verstovsek, Srdan, et al.
Publicado: (2018)

Hemophagocytic lymphohistiocytosis in adults: An under recognized entity
por: Shah, Abdul Rashid, et al.
Publicado: (2016)

P1018: UPDATED RESULTS FROM MANIFEST ARM 2: EFFICACY AND SAFETY OF PELABRESIB (CPI-0610) AS ADD-ON TO RUXOLITINIB IN MYELOFIBROSIS
por: Kremyanskaya, Marina, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5sknmjbn3t1nvj01un2p0ip7fc